Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis

Amlitelimab treatment significantly reduced clinical and biomarker responses, and was well tolerated in adults with AD through week 52. Sustained responses were observed in the majority of patients for 28 weeks after they had stopped taking amlitelimab.

Authors

Institutions

Publication Details

Journal
Journal of Allergy and Clinical Immunology
Published
2024-11-08
DOI
https://doi.org/10.1016/j.jaci.2024.10.031
Citations
37
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
12.08
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis

Peter Foley, Kim Papp, Anne-Catherine Solente, Fabrice Hurbin et al.
37 citations
Journal of Allergy and Clinical Immunology
Asthma and respiratory diseases
12.08
article

Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis

Peter Foley, Kim Papp, Anne-Catherine Solente, Fabrice Hurbin, Charles W Lynde, John T. O’Malley, Sonya Davey, Karl Yen, Xiaodan Wei, Margitta Worm, Samuel Adelman, Charlotte Bernigaud, Adam Reich, Chih‐Hung Lee, Yoko Kataoka, Andrew Blauvelt, Natalie Rynkiewicz, Stephan Weidinger, Christine Weber, Wanling Wong
article en
37 citations

Abstract

Amlitelimab treatment significantly reduced clinical and biomarker responses, and was well tolerated in adults with AD through week 52. Sustained responses were observed in the majority of patients for 28 weeks after they had stopped taking amlitelimab.

Journal of Allergy and Clinical ImmunologyVol. 155(4)
Chang Gung University (TW), Sanofi (France) (FR), Osaka Prefectural Medical Center (JP), Kaohsiung Chang Gung Memorial Hospital (TW), Information Technology Association of America (US), Sanofi (Switzerland) (CH), Sanofi (United States) (US), University Hospital Schleswig-Holstein (DE), Probity Medical Research (CA), Sanofi (United Kingdom) (GB), Skin Health Institute (AU), Charité - Universitätsmedizin Berlin (DE), University of Lübeck (DE), University of Rzeszów (PL)
Good health and well-being
Openalex Percentile: Top 1%
Asthma and respiratory diseases
12.08
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.